欧林生物: 成都欧林生物科技股份有限公司第六届监事会第十三次会议决议公告

Meeting Overview - The sixth session of the Supervisory Board of Chengdu Olin Biological Technology Co., Ltd. was held on June 25, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal regarding the results of the stock issuance to specific targets, affirming the legality and compliance of the issuance process [2]. - The signing of a subscription agreement with specific targets was approved, ensuring no harm to the interests of the company and its shareholders [2]. - The authenticity, accuracy, and completeness of the fundraising prospectus for the stock issuance were confirmed, with no misleading statements or omissions [2]. - The revised plan for the stock issuance was approved, aligning with relevant laws and the company's specific circumstances [2][4]. - The analysis report for the stock issuance plan was deemed compliant with legal regulations [4]. - The feasibility analysis report for the use of raised funds was approved, confirming its alignment with legal requirements [5]. - The report on the use of previously raised funds as of March 31, 2025, was approved, with an audit report from Zhongqin Wanxin Accounting Firm [5]. - The detailed report on non-operating gains and losses for the last three years and one quarter was approved, with an audit report confirming its compliance [6]. - The internal control evaluation report for the first quarter of 2025 was approved, reflecting the actual internal control situation [7]. - The measures to mitigate the dilution of immediate returns from the stock issuance were approved, along with commitments from relevant parties [8]. - The explanation regarding the fundraising's alignment with technology innovation was approved, confirming its compliance with legal regulations [9]. - The establishment of a dedicated account for the raised funds and the authorization to sign a regulatory agreement was approved, ensuring proper management of the funds [9].